AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

1 North Waukegan Road
North Chicago, IL 60064

Tel: 1-800-255-5162

Visit website

Email Us

Stock Symbol: ABBV
Stock Exchange: NYSE

NEWS

Business

Liquidia Technologies Appoints Industry Veteran Katie Rielly-Gauvin to Board of Directors

Liquidia Technologies, Inc. announced the appointment of Katie Rielly-Gauvin, Vice President of Global Commercial Development at AbbVie, to the Company’s Board of Directors as a Class II director with a term expiring at the 2020 annual meeting of stockholders and to the Company’s Research and Development Committee and Nominating & Governance Committee.

November 3, 2019

4 min read

Drug Development

AbbVie’s Rinvoq Likely Headed for Another Approval in a Crowded Inflammatory Market

On the same day Novartis announced that its Cosentyx didn’t prove itself superior to AbbVie’s Humira in psoriatic arthritis, AbbVie announced that its Rinvoq met the primary endpoint in active psoriatic arthritis in its SELECT-PsA 2 Phase III trial.

November 1, 2019

2 min read

Mark Terry

Drug Development

Novartis’ Cosentyx Narrowly Misses Beating Out AbbVie’s Humira in Arthritis Trial

Novartis is careful to note that Cosentyx showed “numerically higher results versus Humira,” and that there are some statistically significant advantages of the drug over Humira.

November 1, 2019

3 min read

Mark Terry

Business

Disc Medicine Closes $50 Million Series A and Inks Licensing Deal with AbbVie

Disc Medicine is focused on hepcidin biology to restore red blood cell production in hematologic diseases.

October 29, 2019

3 min read

Mark Terry

BioMed X Completes Alzheimer’s Disease Research Project

BioMed X announced the successful completion of their first research collaboration project with AbbVie in the field of tau-mediated neurodegeneration in Alzheimer’s disease.

October 28, 2019

2 min read

Business

Cystic Fibrosis Foundation Licenses Experimental Compound to AbbVie

AbbVie will work to develop a cystic fibrosis transmembrane conductance regulator potentiator compound that it licensed from the Foundation.

October 24, 2019

2 min read

Mark Terry

Business

Generational Priorities: What Baby Boomers, Gen-Xers and Millennials Think Makes an Ideal Employer

When it comes to specific attributes, having the opportunity to do interesting and meaningful work, securing a competitive salary and having access to quality health benefits were the most important. Here are some differences when it comes to generational priorities.

October 21, 2019

3 min read

Porschia Parker

Employer Resources

Employees’ Perception vs. Employers’ Reality! New Research Shows the Top 3 Areas of Opportunity

What makes an organization a desirable employer? Do they need to be a large company with a recognizable name? Should the organization pay their employees more than others?

October 11, 2019

4 min read

Porschia Parker

Business

AbbVie Stays Busy While Working to Complete Allergan Acquisition

As the $63 billion acquisition of Allergan by Chicago-based AbbVie slowly churns through the Federal Trade Commission (FTC) process, the company continues to make the news. Here’s a look.

October 11, 2019

3 min read

Mark Terry

JOBS